Biotechnology Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results Read more
Biotechnology MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds – Mind Medicine (NASDAQ:MNMD) Read more
